Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
Two resolute onyx were implanted on the (b)(6) 2022.The patient reported a rash all over the body 14 days after the two stents were implanted.The patient previously had two non-medtronic stent implanted on the (b)(6) 2022 with no issues.The cardiologist and dermatologist were informed of the rash and the patient has been referred to their doctor.The patient underwent skin testing which was positive for cobalt.The patient has known penicillin and shrimp allergy.A zotorolimus allergy is suspected, however, it was not known before.Medications omeprizol and lipitor have been discontinued, and other medications have been switched around to help, but the rash persisted.The patient is taking an antihistamine zyrtec for their symptoms.The rash is since improved and the patient is doing fine.
|